古塞奇尤单抗在系统性初治及富马酸酯无效患者中的长期疗效与撤药后维持:POLARIS Ⅲb期试验II/III部分
POLARIS Ⅲb期试验在系统性初治中重度斑块状银屑病患者中比较古塞奇尤单抗(GUS)与富马酸酯(FAE),第32周GUS组PASI 75应答率98%高于FAE组41%,第56周GUSr-GUS组PASI 90应答率91%,撤药至第100周47%维持PASI≤5,GUS不良事件及停药率低于FAE。
要点
- 系统性初治患者第32周GUS的PASI 75应答率98%,显著高于FAE的41%。
- FAE无效者换用GUS后第56周PASI 90应答率达80%。
- GUS撤药44周后47%患者仍维持PASI≤5。
核心结论
- GUS作为一线系统治疗或FAE无效后的二线治疗,至第100周(含撤药期)仍显示长期临床疗效。
研究设计与样本
- 随机、活性对照、Ⅲb期试验(POLARIS)II和III部分,系统性初治中重度斑块状银屑病患者按1:1随机接受GUS或FAE。
主要发现
- 第32周GUS组98%(54/55)和FAE组41%(14/34)患者为PASI 75应答者。
- 第56周GUSr-GUS、FAEr-FAE和FAEnr-GUS组分别有91%、50%和80%患者达到PASI 90应答。
- 第56周上述三组分别有72%、29%和45%患者DLQI评分为0/1。
- 第100周(撤药44周后)GUS-GUSw组47%(17/36)和FAE-GUSw组25%(3/12)患者维持PASI≤5。
- 总体不良事件和停药率GUS低于FAE。
关键数值与推荐
- PASI 75应答定义为PASI评分改善≥75%。
- PASI 90应答定义为PASI评分改善≥90%。
- 第56周PASI 90应答的GUS治疗患者撤药并随访至应答丢失或第100周。
临床怎么用
- GUS可作为系统性初治中重度斑块状银屑病的一线系统治疗选择。
- FAE治疗无效的中重度斑块状银屑病患者可换用GUS治疗。
- GUS治疗达PASI 90后撤药,部分患者至第100周仍可维持PASI≤5。
局限性
- 结论基于探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The anti-interleukin-23 antibody guselkumab (GUS) demonstrated favourable week 24 efficacy and safety over fumaric acid esters (FAE) in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis (study part I). OBJECTIVES: To compare, in study part II, the sustainability of treatment responses (weeks 24-32) in GUS- and FAE-treated patients and treatment responses (weeks 32-56) in patients treated with GUS and FAE and in FAE nonresponders switching to GUS; and, in part III, to investigate the maintenance of response through week 100 in patients withdrawn from GUS at week 56. METHODS: At week 0, systemic treatment-naïve patients were randomized 1 : 1 to GUS or FAE as per label. At week 32, patients with a Psoriasis Area and Severity Index (PASI) 75 (≥ 75% improvement in PASI score) response (r) continued assigned treatment (GUSr-GUS; FAEr-FAE), whereas nonresponders (nr) received GUS (FAEnr-GUS; GUSnr-GUS). GUS-treated patients with a week 56 PASI 90 response (≥ 90% improvement in PASI score) were withdrawn (w) and followed until loss of response or week 100. RESULTS: At week 32, 98% (n = 54/55) of GUS- and 41% (n = 14/34) of FAE-treated patients were PASI 75 responders. At week 56, 91%, 50% and 80% of GUSr-GUS, FAEr-FAE and FAEnr-GUS patients, respectively, achieved a PASI 90 response; 72%, 29% and 45%, respectively, achieved a Dermatology Life Quality Index score of 0/1. At week 100, 44 weeks postwithdrawal, 47% (n = 17/36) and 25% (n = 3/12) of GUS-GUSw and FAE-GUSw patients, respectively, maintained a PASI score ≤ 5. Overall, the adverse event and discontinuation rates were lower for GUS than FAE. CONCLUSIONS: In these exploratory analyses, GUS, as a first-line systemic treatment or second-line systemic treatment in FAE nonresponders, was associated with long-term clinical efficacy up to week 100, including a withdrawal period.
引用
- Thaçi D, Pinter A, Sebastian M, et al. Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. 2024. PMID: 38133615. doi:10.1093/bjd/ljad523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。